Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Operating Expenses: 2019-2025

Historic Operating Expenses for BridgeBio Pharma (BBIO) over the last 7 years, with Sep 2025 value amounting to $265.9 million.

  • BridgeBio Pharma's Operating Expenses rose 36.72% to $265.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $963.7 million, marking a year-over-year increase of 26.44%. This contributed to the annual value of $814.9 million for FY2024, which is 32.14% up from last year.
  • Per BridgeBio Pharma's latest filing, its Operating Expenses stood at $265.9 million for Q3 2025, which was up 8.60% from $244.8 million recorded in Q2 2025.
  • In the past 5 years, BridgeBio Pharma's Operating Expenses ranged from a high of $265.9 million in Q3 2025 and a low of $128.0 million during Q1 2023.
  • For the 3-year period, BridgeBio Pharma's Operating Expenses averaged around $196.7 million, with its median value being $194.5 million (2024).
  • Per our database at Business Quant, BridgeBio Pharma's Operating Expenses decreased by 27.02% in 2023 and then spiked by 64.68% in 2024.
  • Quarterly analysis of 5 years shows BridgeBio Pharma's Operating Expenses stood at $178.5 million in 2021, then fell by 26.55% to $131.1 million in 2022, then spiked by 36.66% to $179.2 million in 2023, then climbed by 29.44% to $231.9 million in 2024, then skyrocketed by 36.72% to $265.9 million in 2025.
  • Its last three reported values are $265.9 million in Q3 2025, $244.8 million for Q2 2025, and $221.0 million during Q1 2025.